// App-Quantinova.ai

TPS3102 : A first-in-human phase I trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma.

Researchers

Presenter

  • Sarah Nikiforow

Principal Investigators

  • Joana Murad

  • Heather Daley

  • Helene Negre

  • Jake Reder

  • Charles L. Sentman

  • Frederic Lehmann

  • Sarah Snykers

  • Rachel Allen

  • Ilene Galinsky

  • Nikhil C. Munshi

  • Richard M. Stone

  • Robert Soiffer

  • Jerome Ritz

  • Susanne H.C. Baumeister

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Celdara Medical, LLC, Lebanon, NH

  • Geisel School of Medcn At Dartmouth, Lebanon, NH

  • Celyad, SA, Mont Saint Guibert, Belgium

  • Dana-Farber Cancer Institute, Children's Hospital, Boston, MA

Locations

  • United States

  • Belgium

Companies

  • Celdara Medical, LLC

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Solid malignancies

Biomarkers

  • Natural killer group 2D

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

  • First-In-Human

Phase

  • I

Study Id's

  • NCT02203825

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved